Preview Mode Links will not work in preview mode

Aug 18, 2020

A roundtable discussion with Drs Carla Casulo and John P Leonard on recent developments in the treatment of follicular lymphomas, including the following topics:

  • Current management of newly diagnosed follicular lymphoma (FL); choice of observation versus rituximab monotherapy (00:00)
  • Association between vitamin D insufficiency and outcomes for patients with FL   5m41s
  • Efficacy and tolerability of obinutuzumab/bendamustine for patients with newly diagnosed FL (9:44)
  • Activity of lenalidomide/rituximab (R2) in patients with FL (15:56)
  • Biology of FL; criteria for initiating therapy after diagnosis (20:55)
  • Results of the Phase III GALLIUM study of obinutuzumab or rituximab, each in combination with chemotherapy, followed by maintenance obinutuzumab or rituximab for patients with untreated, advanced FL (31:02)
  • Phase III RELEVANCE trial evaluating R2 versus rituximab/chemotherapy, each followed by maintenance rituximab, as first-line therapy for advanced FL (34:58)
  • Selection and sequencing of therapies for relapsed/refractory FL; management of early progression of disease (41:07)
  • Biologic predictors of early relapse; role of transplant for patients with FL (47:20)
  • Activity and tolerability of CAR (chimeric antigen receptor) T-cell therapies for FL (54:39)
  • Response to the PI3 kinase inhibitor umbralisib in combination with obinutuzumab for relapsed FL (58:02)
  • Outcomes for patients with early relapse of FL in the National LymphoCare Study (1:04:35)
  • Integration of the PI3 kinase inhibitors idelalisib, copanlisib and duvelisib into the management of FL (1:12:18)
  • Mechanism of action, efficacy and tolerability of the recently approved EZH2 inhibitor tazemetostat for relapsed/refractory FL (1:22:01)
  • Results of the Phase II ZUMA-5 study of axicabtagene ciloleucel for patients with relapsed/refractory indolent non-Hodgkin lymphoma (1:26:32)
  • Biologic rationale for the use of the novel bispecific antibody mosunetuzumab for relapsed/refractory FL (1:30:40)
  • Novel agents and approaches under investigation for patients with FL (1:34:58)

CME information and select publications